Olipass Corp
244460
Company Profile
Business description
Olipass Corp is a South Korea based biotechnology company engaged in developing its platform OliPass PNA which focuses on introducing cationic lipid moiety onto nucleobase. Its pipeline products include SC Injection, Hyper Cholesterolemia, Chemo/Radio-sensitizer, and Type II Diabetes among others.
Contact
16-4, 16 Beon-gil, Dongbaek Jungang-ro
Ace Dongbaek Tower 20th Floor
Giheung-gu
Yongin17015
KORT: +82 3180608200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
57
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,369.30 | 4.70 | -0.06% |
| CAC 40 | 7,696.27 | 31.66 | -0.41% |
| DAX 40 | 23,144.81 | 199.73 | -0.86% |
| Dow JONES (US) | 41,218.83 | 98.60 | -0.24% |
| FTSE 100 | 8,594.69 | 1.66 | -0.02% |
| HKSE | 22,662.71 | 158.03 | 0.70% |
| NASDAQ | 17,844.24 | 133.49 | -0.74% |
| Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
| NZX 50 Index | 12,421.09 | 0.16 | -0.00% |
| S&P 500 | 5,650.38 | 36.29 | -0.64% |
| S&P/ASX 200 | 8,151.40 | 6.40 | -0.08% |
| SSE Composite Index | 3,316.11 | 37.08 | 1.13% |